A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.
We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4(+) T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.
Li
Gang
G
Department of Pediatrics, University of Arizona, Tucson, AZ 85724, USA.
Andreansky
Samita
S
Helguera
Gustavo
G
Sepassi
Marjan
M
Janikashvili
Nona
N
Cantrell
Jessica
J
Lacasse
Collin L
CL
Larmonier
Nicolas
N
Penichet
Manuel L
ML
Katsanis
Emmanuel
E
D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis*; D000920:Antibody-Dependent Cell Cytotoxicity; D019496:Cancer Vaccines / Q000276:immunology*; D002460:Cell Line; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D007106:Immune Sera; D008325:Mammary Neoplasms, Experimental / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D018832:Molecular Chaperones / Q000378:metabolism*
D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D007106:Immune Sera; D018832:Molecular Chaperones